As Retatrutide is not yet licensed, full information on contraindications, drug interactions, and use in special populations (such as pregnancy, breastfeeding, severe renal or hepatic impairment) is not yet finalised
Researchers comparing non-incretin options can also review the tesofensine protocol and SLU-PP-332 protocol
It may help to focus on making whole, unprocessed foods the majority of your diet and limiting those that are refined and high in sugar, Bannan adds
For those researching long-term peptide strategies, the broader landscape of weight management peptides offers numerous options for sustained metabolic support
Average results varied by dose and time frame: Participants taking a 4 mg dose lost 47.2 pounds (lb), or about 19 percent of their starting body weight
Semaglutide can cause nausea, vomiting, or reduced appetite, particularly during the early stages of treatment